Analysis of behavior-related adverse experiences in clinical trials of montelukast George Philip, MD, Carolyn M. Hustad, PhD, Marie-Pierre Malice, PhD, Gertrude Noonan, BA, Alan Ezekowitz, MBChB, D Phil, Theodore F. Reiss, MD, Barbara Knorr, MD Journal of Allergy and Clinical Immunology Volume 124, Issue 4, Pages 699-706.e8 (October 2009) DOI: 10.1016/j.jaci.2009.08.011 Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 1 Patients with BRAEs. Plot showing the ORs and 95% CIs for all BRAEs, Psych-SOC plus OtherSelectPTs, and Akath-PTs. Journal of Allergy and Clinical Immunology 2009 124, 699-706.e8DOI: (10.1016/j.jaci.2009.08.011) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Time to discontinuation: Kaplan-Meier cumulative incidence of discontinuation for any reason for patients included in the analysis of BRAEs. Journal of Allergy and Clinical Immunology 2009 124, 699-706.e8DOI: (10.1016/j.jaci.2009.08.011) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions